Viberzi Pancreatitis Claims in 2026: 120 FDA Reports, 2 Deaths, and the No-Gallbladder Rule
Viberzi pancreatitis claims turn on an FDA warning: in March 2017, the agency said the drug should never be given to patients without a gallbladder, after 120 reports of serious pancreatitis or death. If you lost your gallbladder and were still prescribed Viberzi, prescription history is the heart of the claim.
For plain-language explanations of drug-safety stories and money questions, see Problem Solved on YouTube.
Key Facts
- Viberzi (eluxadoline) was approved in May 2015 to treat irritable bowel syndrome with diarrhea (IBS-D).
- On March 15, 2017, the FDA warned that Viberzi should not be used in patients without a gallbladder.
- Between May 2015 and February 2017, the FDA received 120 reports of serious pancreatitis or death linked to the drug.
- Of the 68 patients whose gallbladder status was reported, 56 did not have a gallbladder.
- 76 patients were hospitalized and 2 died; both deaths were in patients without a gallbladder.
What Viberzi Is — and What Pancreatitis Means
Irritable bowel syndrome with diarrhea, shortened to IBS-D, is a long-term bowel disorder marked by cramping, urgency, and frequent loose stools. Viberzi, generic name eluxadoline, was approved in May 2015 to calm that diarrhea by slowing bowel contractions. It acts on opioid receptors in the gut, which is also why it can affect the small muscle valve controlling bile and pancreatic juices, a valve doctors call the sphincter of Oddi. Pancreatitis is inflammation of the pancreas, the organ behind the stomach that makes digestive enzymes and insulin; in severe form it brings sudden, intense upper abdominal pain, nausea, and vomiting, and can require hospital treatment.
The 2017 FDA Warning in Detail
The FDA safety communication of March 15, 2017, reviewed every serious report since the drug reached the market. Between May 2015 and February 2017, the FDA Adverse Event Reporting System collected 120 reports of serious pancreatitis or death in patients taking eluxadoline, and of the 68 patients whose gallbladder status was recorded, 56 had no gallbladder, most taking the 75 mg dose recommended for patients without one. Two details matter most for claims: among the 84 cases reporting when symptoms began, 48 began after only one or two doses, and 76 patients were hospitalized, with both reported deaths in patients without a gallbladder.
The No-Gallbladder Rule
After that review the FDA position became absolute: health professionals should not prescribe Viberzi to patients without a gallbladder, and such patients should not take it. A cholecystectomy is the surgical removal of the gallbladder, usually after gallstone trouble, and a prescribing doctor should know about it from the patient's history. The drug's label now carries that restriction, so a prescription for a patient without a gallbladder after March 2017 is hard to describe as an innocent oversight. It is the dividing line between a strong claim and a weak one: a patient who still has a gallbladder faces a harder causation argument.
What a Claim Has to Prove
A claim is built from records, in this order. First, proof of gallbladder removal before the first Viberzi prescription. Second, pharmacy records showing the drug, dose, and dates, ideally continuing after March 2017. Third, hospital records diagnosing acute pancreatitis, with onset measured against the first doses. Fourth, the absence of a competing explanation: gallstones, heavy alcohol use, and very high triglycerides all cause pancreatitis, and a treating doctor's note linking the episode to the drug, written at the time, carries far more weight than a retrospective opinion.
Who Benefits From This — and Who Does Not
Patients without a gallbladder who were prescribed Viberzi and then suffered serious pancreatitis benefit most, because their history matches the FDA warning exactly; the clearer the prescription-after-warning timeline, the stronger the claim. Families of patients who died after taking Viberzi without a gallbladder also benefit, since the FDA record documents two such deaths. Readers weighing other drug-injury claims may find the same record-first approach in our guide to Ozempic gastroparesis claims and in the proton pump inhibitor kidney lawsuits, where the warning history likewise decides who qualifies.
Patients who still have a gallbladder do not fit the core claim, because the warning targeted only the no-gallbladder group, and patients who took Viberzi with no pancreatic injury have no injury to claim. Patients whose pancreatitis has a separate established cause, such as gallstones or heavy alcohol use documented before the prescription, will struggle to show the drug caused the episode, and patients whose only complaint is that Viberzi did not relieve their IBS-D symptoms do not have a pancreatitis claim at all.
What to Do Next
Medical care comes first. Severe abdominal pain, persistent vomiting, or pain radiating to the back after starting Viberzi needs emergency attention; tell the treating team exactly which drug you took and when. Keep the prescription bottles, pharmacy printout, and discharge summaries, and note the first-dose and symptom dates while memory is fresh. Then have a drug-injury attorney review the file before any deadline runs: deadlines vary by state and usually run from when the patient knew, or should have known, the drug may have caused the injury. Compensation varies widely by case, and most settlements are confidential, so no honest guide can promise a figure.
Frequently Asked Questions
Who benefits from a Viberzi pancreatitis claim?
Patients without a gallbladder who were prescribed Viberzi and then suffered serious pancreatitis benefit most, especially where prescriptions continued after the March 2017 warning, as do families of patients who died after taking it.
Who does not benefit from this topic?
Patients who still have a gallbladder, patients uninjured by Viberzi, and patients whose pancreatitis has a separate established cause do not fit the core claim.
How do I start a Viberzi claim?
Get medical care first, then gather your gallbladder-surgery record, pharmacy history showing Viberzi prescriptions and dates, and hospital records for the pancreatitis episode, and have a drug-injury attorney review them before your state's deadline.
What did the FDA actually find in 2017?
Between May 2015 and February 2017 the FDA received 120 reports of serious pancreatitis or death; 76 patients were hospitalized and 2 died, both without a gallbladder, and 48 cases began after only one or two doses.
Has Viberzi been recalled?
No. The FDA issued a safety communication and the label now states the drug should not be used in patients without a gallbladder, and claims focus on prescriptions that ignored that warning.
General information only — not legal or medical advice. If you have symptoms of pancreatitis, seek care promptly and discuss medicine changes with your doctor.